Dianthus Therapeutics (DNTH) Competitors $20.77 -1.50 (-6.74%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DNTH vs. AMRX, SRRK, ZLAB, JANX, CPRX, IOVA, TWST, LBPH, ARWR, and PTGXShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Amneal Pharmaceuticals (AMRX), Scholar Rock (SRRK), Zai Lab (ZLAB), Janux Therapeutics (JANX), Catalyst Pharmaceuticals (CPRX), Iovance Biotherapeutics (IOVA), Twist Bioscience (TWST), Longboard Pharmaceuticals (LBPH), Arrowhead Pharmaceuticals (ARWR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Amneal Pharmaceuticals Scholar Rock Zai Lab Janux Therapeutics Catalyst Pharmaceuticals Iovance Biotherapeutics Twist Bioscience Longboard Pharmaceuticals Arrowhead Pharmaceuticals Protagonist Therapeutics Amneal Pharmaceuticals (NASDAQ:AMRX) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends. Which has more risk & volatility, AMRX or DNTH? Amneal Pharmaceuticals has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Which has higher valuation and earnings, AMRX or DNTH? Dianthus Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.39B1.09-$83.99M-$0.68-12.37Dianthus Therapeutics$2.83M217.24-$43.56M-$2.50-8.31 Do insiders and institutionals hold more shares of AMRX or DNTH? 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is AMRX or DNTH more profitable? Amneal Pharmaceuticals has a net margin of -6.88% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals-6.88% -346.26% 4.85% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Does the media prefer AMRX or DNTH? In the previous week, Dianthus Therapeutics had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Dianthus Therapeutics and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.88 beat Dianthus Therapeutics' score of 0.06 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate AMRX or DNTH? Amneal Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 18.91%. Dianthus Therapeutics has a consensus price target of $46.43, suggesting a potential upside of 123.54%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Does the MarketBeat Community prefer AMRX or DNTH? Dianthus Therapeutics received 7 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. Likewise, 100.00% of users gave Dianthus Therapeutics an outperform vote while only 93.75% of users gave Amneal Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmneal PharmaceuticalsOutperform Votes1593.75% Underperform Votes16.25%Dianthus TherapeuticsOutperform Votes22100.00% Underperform VotesNo Votes SummaryDianthus Therapeutics beats Amneal Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$659.12M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-8.314.8389.0213.30Price / Sales217.24372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book1.827.876.085.74Net Income-$43.56M$153.61M$119.07M$225.93M7 Day Performance-18.52%-2.00%-1.84%-1.32%1 Month Performance-26.81%-7.47%-3.65%0.60%1 Year Performance80.61%31.80%31.62%26.23% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.5021 of 5 stars$20.77-6.7%$46.43+123.5%+78.7%$659.12M$2.83M-8.3180AMRXAmneal Pharmaceuticals2.9437 of 5 stars$8.41-0.4%$10.00+18.9%+86.9%$2.61B$2.39B0.007,700Insider TradeSRRKScholar Rock4.1709 of 5 stars$27.86flat$34.00+22.0%+137.1%$2.61B$33.19M0.00140ZLABZai Lab2.9574 of 5 stars$26.23+0.3%$52.50+100.2%-7.2%$2.60B$266.72M-9.472,175Analyst RevisionJANXJanux Therapeutics3.5908 of 5 stars$48.96-0.1%$66.44+35.7%+441.0%$2.57B$8.08M0.0030CPRXCatalyst Pharmaceuticals4.7417 of 5 stars$21.15-1.1%$31.14+47.2%+54.3%$2.55B$398.20M17.92167Analyst ForecastIOVAIovance Biotherapeutics4.0475 of 5 stars$8.14-0.6%$22.33+174.4%+48.3%$2.50B$1.19M0.00500Options VolumeTWSTTwist Bioscience4.1398 of 5 stars$41.11-0.5%$51.78+25.9%+66.2%$2.45B$312.97M0.00990Analyst ForecastAnalyst RevisionLBPHLongboard Pharmaceuticals1.4685 of 5 stars$59.77-0.1%$59.56-0.4%+1,283.6%$2.34BN/A0.0020ARWRArrowhead Pharmaceuticals3.5698 of 5 stars$18.71+0.6%$45.33+142.3%-35.3%$2.31B$240.74M0.00400Upcoming EarningsAnalyst ForecastPTGXProtagonist Therapeutics3.0192 of 5 stars$40.65+5.2%$53.57+31.8%+135.8%$2.30B$60M15.28125Analyst ForecastNews Coverage Related Companies and Tools Related Companies Amneal Pharmaceuticals Alternatives Scholar Rock Alternatives Zai Lab Alternatives Janux Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Iovance Biotherapeutics Alternatives Twist Bioscience Alternatives Longboard Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DNTH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts